[Japon] A tale of two Japanese drugs in tests to fight COVID-19
Auteur : Rocky Swift, Christine Soares (Additional reporting by Sangmi Cha in Seoul; Editing by Elyse Tanouye and Carmel Crimmins).
Production : Reuters, agence de presse mondiale et généraliste fondée en 1851 à Londres.
Diffusion : site de Reuters
Date : 13 mai 2020
In the global hunt for coronavirus treatments, a Japanese antiviral medicine known as Avigan has won plaudits from Prime Minister Shinzo Abe and $128 million in government funding.
Source : Rocky Swift, Christine Soares, « A tale of two Japanese drugs in tests to fight COVID-19 », Reuters, 13/05/2020. URL : https://www.reuters.com/article/us-health-coronavirus-japan-medicine/a-tale-of-two-japanese-drugs-in-tests-to-fight-covid-19-idUSKBN22O3DC (consulté le 13/05/2020).
Photo « à la une » : Tablets of Avigan (generic name : Favipiravir), a drug approved as an anti-influenza drug in Japan and developed by drug maker Toyama Chemical Co, a subsidiary of Fujifilm Holdings Co. are displayed during a photo opportunity at Fujifilm’s headquarters in Tokyo October 22, 2014. © Reuters / Issei Kato